A significant decrease in FASN staining in the viable tissue fraction was found in tumours treated with the FASN inhibitor orlistat alone or in combination with cisplatin when compared to vehicle controls (p < 0.0001 for ORL, ORL/CP D0 and p < 0.001 for ORL/CP D2). Here, FASN is linked to neoplasm.